69 filings
8-K
APTX
Aptinyx Inc.
21 Dec 23
Other Events
10:52am
8-K
APTX
Aptinyx Inc.
18 Dec 23
Other Events
5:00pm
8-K
APTX
Aptinyx Inc.
3 Jul 23
Departure of Directors or Certain Officers
1:31pm
8-K
APTX
Aptinyx Inc.
11 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:01am
8-K
APTX
Aptinyx Inc.
5 May 23
Departure of Directors or Certain Officers
8:01am
8-K
ubqccnx
25 Apr 23
Termination of a Material Definitive Agreement
9:24am
8-K
w2pdvrc 5vutn
18 Apr 23
Departure of Directors or Certain Officers
4:15pm
8-K
t7q771 i3kua71o
30 Mar 23
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
4:15pm
8-K
9fg2d
1 Mar 23
Cost Associated with Exit or Disposal Activities
8:31am
8-K
f4slfz9r07551
27 Feb 23
NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx
4:03pm
8-K
kc3rsljnm3s 9u
8 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
gxy2vy8wq
1 Dec 22
Departure of Directors or Certain Officers
4:06pm
8-K
1t6nfg76 4z6
8 Nov 22
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
4:15pm
8-K
z86j9zkz6hqf z4q
25 Aug 22
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
11:45am
8-K
c84yw b63m
12 Aug 22
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
7:15am
8-K
n2z o4d4l5h
4 Aug 22
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
4:15pm
8-K
r8kp3e
10 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
qqy3e9
31 May 22
Submission of Matters to a Vote of Security Holders
4:45pm
8-K
7njmm pffrrygp9
12 May 22
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
4:16pm
8-K
dl47z0vrak 94
19 Apr 22
Other Events
7:00am